Traws Pharma grants 84,000 options to CMO

Traws Pharma, Inc. granted Chief Medical Officer Robert Redfield a stock option award covering 84,000 shares of common stock.

Accepted by SEC EDGAR 07/14/2026 - 08:23 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Traws Pharma, Inc. granted Chief Medical Officer Robert Redfield a stock option award covering 84,000 shares of common stock. The options have an exercise price of $0.68 per share and expire on 2036-07-09. The award was granted at a transaction price of $0.00 per option under the company’s 2021 Incentive Compensation Plan, as amended. According to the award terms, the options will vest 100% on the first anniversary of the 2026-07-09 grant date. Following this grant, Redfield directly holds options for 84,000 underlying shares.

Insider Trade Summary

Grant/Award: 84,000 shares

Grant/Award 1 txn

Insider Redfield Robert

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	84,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 84,000 contracts (Direct)

Holdings Before and After: Stock Option (right to buy), 0 to 84,000 contracts (Direct)

Footnotes (1)

1. F1. Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

Key Figures

Options Granted: 84,000 options Exercise Price: $0.68 per share Expiration Date: 2036-07-09 +3 more

6 metrics

Options Granted 84,000 options Stock option award to Chief Medical Officer on 2026-07-09

Exercise Price $0.68 per share Exercise price of stock options underlying 84,000 shares

Expiration Date 2036-07-09 Expiration of the granted stock options

Vesting Schedule 100% after 1 year Options vest 100% on first anniversary of 2026-07-09 grant date

Post-Grant Holdings 84,000 options Total stock options held by Robert Redfield following this grant

Transaction Price $0.00 per option Reported transaction price per option for the grant

Key Terms

Stock Option, 2021 Incentive Compensation Plan, exercise price, vesting

4 terms

Stock Option financial

"Represents stock options awarded by the Issuer's compensation committee"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

2021 Incentive Compensation Plan financial

"under the Issuer's 2021 Incentive Compensation Plan, as amended"

exercise price financial

"conversion_or_exercise_price: "0.6800" for the stock option grant"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The stock options under this award will vest 100% on the first anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity award did Traws Pharma (TRAW) grant to its Chief Medical Officer?

Traws Pharma granted Chief Medical Officer Robert Redfield 84,000 stock options. These options have an exercise price of $0.68 per share, expire on 2036-07-09, and were issued under the company’s 2021 Incentive Compensation Plan.

When do Robert Redfield’s new TRAW stock options vest?

Robert Redfield’s 84,000 TRAW stock options will vest 100% on the first anniversary of the grant date. The grant date is 2026-07-09, so full vesting occurs one year after that date, based on the award’s stated terms.

What is the exercise price of the new TRAW options granted to the CMO?

The stock options granted to the TRAW Chief Medical Officer carry an exercise price of $0.68 per share. Each option is exercisable for one share of Traws Pharma common stock at this price until their stated expiration in 2036.

How many TRAW shares underlie Robert Redfield’s reported stock options after this grant?

After this award, Robert Redfield holds stock options for 84,000 underlying shares of Traws Pharma common stock. The Form 4 reports these as directly owned derivative securities following the compensation-related grant transaction.

Under which plan were the new TRAW stock options to the CMO granted?

The 84,000 TRAW stock options were granted under Traws Pharma’s 2021 Incentive Compensation Plan, as amended and/or restated. The award was approved by the company’s compensation committee of independent directors, according to the filing footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Redfield Robert

(Last) (First) (Middle)

C/O TRAWS PHARMA, INC.

12 PENNS TRAIL

(Street)

NEWTOWN PENNSYLVANIA 18940

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Traws Pharma, Inc. [ TRAW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.68	07/09/2026		A		84,000		07/09/2027(1)	07/09/2036	Common Stock	84,000	$0	84,000	D

Explanation of Responses:

1. Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

	/s/ Robert Redfield	07/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)